Becton, Dickinson and Company (NYSE:BDX) Given New $225.00 Price Target at Royal Bank Of Canada

Becton, Dickinson and Company (NYSE:BDX) had its price target boosted by investment analysts at Royal Bank Of Canada from $190.00 to $225.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “sector perform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada‘s price objective points to a potential upside of 5.74% from the company’s previous close.

Several other analysts also recently commented on BDX. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Zacks Research upgraded Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Weiss Ratings raised shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Finally, Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $191.20.

Becton, Dickinson and Company Stock Down 0.4%

BDX traded down $0.77 during trading on Friday, reaching $212.78. 839,852 shares of the stock were exchanged, compared to its average volume of 2,431,693. The stock has a market cap of $58.63 billion, a P/E ratio of 64.10, a price-to-earnings-growth ratio of 14.10 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock’s 50 day moving average price is $187.69 and its two-hundred day moving average price is $170.23. Becton, Dickinson and Company has a twelve month low of $137.35 and a twelve month high of $214.88.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. During the same period last year, the firm posted $3.96 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock buyback plan on Thursday, November 5th that authorizes the company to buy back 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In related news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 6,907 shares of company stock worth $1,269,128. Company insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors have recently added to or reduced their stakes in BDX. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $3,721,533,000. State Street Corp increased its holdings in Becton, Dickinson and Company by 8.5% in the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after acquiring an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC raised its stake in Becton, Dickinson and Company by 15.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares during the period. Bank of America Corp DE bought a new stake in Becton, Dickinson and Company in the 2nd quarter valued at about $474,993,000. Finally, Beutel Goodman & Co Ltd. lifted its holdings in Becton, Dickinson and Company by 9.0% during the third quarter. Beutel Goodman & Co Ltd. now owns 1,835,571 shares of the medical instruments supplier’s stock valued at $328,567,000 after purchasing an additional 150,931 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BDX reported fiscal Q4 adjusted EPS of $4.15 and revenue of $5.27 billion, topping estimates; revenue grew 5.4% year over year. For fiscal 2026, free cash flow rose 42.5% to $2.9 billion. BD fiscal 2026 results
• Positive Sentiment: The board authorized repurchases of up to 10 million shares—about 3.6% of shares outstanding—and raised the quarterly dividend 1% to $1.06, marking the company’s 55th consecutive annual increase. Dividend and buyback announcement
• Positive Sentiment: Evercore ISI raised its price target to $230 from $210, signaling a more favorable view of BDX’s prospects. Evercore target change
• Neutral Sentiment: Piper Sandler raised its target from $175 to $200 but maintained a neutral rating; the new target is below the recent share price, reflecting a more cautious assessment. Piper Sandler rating
• Negative Sentiment: Despite beating Q4 estimates, BDX’s fiscal 2027 revenue outlook was described as subdued and slightly below expectations, raising concerns about growth and weighing on the shares after the results. Fiscal 2027 outlook report

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.